Printer Friendly

CAMBRIDGE BIOTECH AND DYNAGEN SIGN AGREEMENT FOR WORLDWIDE DISTRIBUTION OF DYNAGEN'S NEW TUBERCULOSIS TESTS

 WORCESTER, Mass., Dec. 16 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ: CBCX) today announced it has finalized a worldwide license and supply agreement with DynaGen, Inc. (NASDAQ: DYGN) under which it will license certain proprietary DynaGen technology for the development of tuberculosis (TB) and other mycobacteria diagnostic products. The market for TB testing devices is estimated to be over $20 million by 1994 and is expected to grow at an annual rate of 9 percent. These products will be developed by Cambridge Biotech's Diagnostics Division.
 Cambridge Biotech will use the DynaGen-developed technology to produce serology tests in the EIA microwell format as well as in rapid formats such as Cambridge Biotech's slide immunoassay. Under terms of the contract, DynaGen will supply Cambridge Biotech with the antigen to be used in the tests as well as assist with final development of the products, which will be distributed in the U.S. by Cambridge Biotech's direct sales force and internationally by Cambridge Biotech's network of independent distributors. DynaGen has reserved manufacturing and marketing rights to certain of its other mycobacterial testing technologies.
 TB is an opportunistic disease which is fast re-emerging as a significant health threat in both the United States and throughout the world. The disease impacts patients who are immunocompromised, particularly by HIV, and increasingly drug-resistant strains of TB have recently emerged. The World Health Organization estimates that some 20 million people worldwide have active TB, that eight million new cases are discovered annually, and that three million people die each year from TB.
 Dr. Patrick J. Leonard, president and CEO of Cambridge Biotech commented, "These products are a logical addition to Cambridge Biotech's $25 million diagnostics division because they provide entry into an important new area of testing in the world health care marketplace." He added, "This is also an example of Cambridge Biotech's corporate strategy to form corporate alliances and establish licensing rights with industry partners to capitalize on proprietary technologies."
 "I am pleased that Cambridge Biotech, with its established presence in the HIV testing marketplace through its line of high-quality diagnostics products, is adding DynaGen's TB tests to its product line," said Dr. Indu Muni, president and CEO of DynaGen, Inc. "Cambridge Biotech is a successful company with a worldwide reach that provides a tremendous opportunity for introducing these important new technologies to the market."
 Cambridge Biotech Corporation is a leading diagnostics and vaccine company involved in infectious diseases. The company is developing vaccines, adjuvants and diagnostics for humans and animals.
 DynaGen, Inc., a biotechnology company, develops diagnostic and therapeutic products for human and veterinary health care. The company made its initial public offering in August 1990 and completed a secondary offering in October 1992.
 -0- 12/16/92
 /CONTACT: Peter P. Hartman, Vice President-Finance and Chief Financial Officer, Cambridge Biotech Corporation, 508-797-5777; or Jack Barlow, Senior Vice President-Corporate Development, DynaGen, Inc., 617-491-2527/
 (CBCX DYGN)


CO: Cambridge Biotech Corporation; DynaGen, Inc. ST: Massachusetts IN: MTC SU:

DH -- NE002 -- 7515 12/16/92 07:05 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 16, 1992
Words:496
Previous Article:MASSACHUSETTS SMALL-BUSINESS OWNERS OPTIMISTIC ABOUT 1993: FLEET POLL SHOWS OWNERS EXPECT STRONG EMPLOYMENT EXPANSION, SUPPORT PRIVATIZATION
Next Article:CENTEL WILL ADJOURN SHAREOWNER MEETING UNTIL FINAL VOTE TALLY
Topics:


Related Articles
CAMBRIDGE BIOTECH AND GULL LABORATORIES ENTER MANUFACTURING/DISTRIBUTION AGREEMENT
CAMBRIDGE BIOTECH CORPORATION ACQUIRES RIGHTS TO DYNAGEN'S RAPID ANTIBODY TESTS FOR TUBERCULOSIS AND MYCOBACTERIA
CAMBRIDGE BIOTECH CORPORATION ACQUIRES RIGHTS TO DYNAGEN'S RAPID ANTIBODY TESTS FOR TUBERCULOSIS AND MYCOBACTERIA
CAMBRIDGE BIOTECH SIGNS AGREEMENT WITH BIOMERIEUX TO SELL ITS RETROVIRAL DIAGNOSTIC BUSINESS
CAMBRIDGE BIOTECH SIGNS AGREEMENT WITH CARTER-WALLACE TO SELL ITS ENTERICS DIAGNOSTIC BUSINESS
DynaGen, Inc. to Acquire Superior Pharmaceutical Company Acquisition to Generate $30 Million Revenue Base
DynaGen, Inc. Completes Acquisition of Superior Pharmaceutical Company
DynaGen, Inc. Extends Common Stock Purchase Warrants (DYGNW)
DynaGen, Inc. Announces Letter of Intent to Acquire Generic Distributors Limited Partnership

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters